Gastrointestinal Drugs Market

An increase in the prevalence of gastrointestinal illnesses is driving the market growth

Market CAGR for gastrointestinal drugs is being driven. The market expansion is estimated to be throughout the forecasted period to be aided by the rising prevalence of gastrointestinal illnesses. For instance, according to a report from the International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) in July 2022, the prevalence of gastroesophageal reflux disease (GERD) in the world's populations in 2014 ranged from 18 to 28% in North America, 9 to 26% in Europe, 9 to 33% in the Middle East, and 3 to 8% in East Asia, among other places.

Additionally, the  increase in the prevalence of gastrointestinal disorders is a significant driver of the market's expansion for gastrointestinal medications. On the other hand, substantial funding, particularly in scientific research for the development and advancement of these medications, as well as growing awareness about the effectiveness of the treatments and the healing process, are both considerably boosting the market's growth. Additionally, this market is anticipated to grow rapidly in the upcoming years due to technological developments in the treatment procedure.

Due to dietary changes, there will likely be a rise in the number of individuals suffering from GI illnesses, boosting the demand for these medications.

Potent pipeline pharmaceuticals like ustekinumab, risankizumab, and ABBV-154 and the rising prescription of biological medications will boost market expansion throughout the anticipated period. In the upcoming years, the market expansion is predicted to be facilitated by the rising number of regulatory approvals for innovative gastrointestinal therapeutic medications. For instance, the U.S. FDA approved RINVOQ (upadacitinib), a prescription drug from AbbVie Inc., in March 2022 to treat severe to moderate ulcerative colitis in adults. The use of RINVOQ to treat individuals who respond poorly to TNF blockers is anticipated to rise.

Likewise, the prescription rate for new & potent medications is anticipated to rise in the upcoming years due to the growing availability of novel treatments for gastrointestinal problems. For instance, BMS gained FDA approval from the United States for Zeposia in May 2021 to treat moderate to severe ulcerative colitis. The only sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of active UC is a deposit. As a result, it is anticipated that the demand for gastrointestinal drugs will increase throughout the projection period due to the high prevalence of gastrointestinal diseases in the population.

Thus, driving the gastrointestinal drugs market revenue.

Par Pharmaceutical, Inc., an operating company of Endo International plc (OTC: ENDPQ) announced in May 2024 that it had started the production of generic ibuprofen-famotidine 800 mg/26.6 mg tablets which are aimed to be copycats for DUEXIS® by Amgen (formerly Horizon Therapeutics). Such pills are used to relieve signs and symptoms of rheumatoid arthritis and osteoarthritis with a reduced risk of ibuprofen-induced stomach or upper intestinal ulcers.

On July 30th, 2023, Viatris Inc. (NASDAQ: VTRS), a global healthcare company and Kindeva Drug Delivery L.P., released Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol as the first generic version of Symbicort® from AstraZeneca under Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). For certain patients with asthma or chronic obstructive pulmonary disease (COPD), Breyna is a drug-device combination product available immediately in two strengths – 80 mcg/4.5 mcg and 160 mcg/4.5 mcg.

This includes people aged six years or older with asthma or COPD like chronic bronchitis/emphysema who take these medications to stop their conditions from worsening but they do not provide relief for sudden breathing difficulties.

The Center for Drug Evaluation and Research (CDER) at The U.S. Food and Drug Administration Approved a Bouquet of Medicines in 2023, Which Will Improve the Quality of Life—and Maybe Prolong Lives—of Patients this Year. In fact," CDER approved 55 novel drugs in that year," according to our annual New Drug Therapy Approvals report. A novel drug contains an active ingredient(s) that has never been previously FDA-approved. We also took other important actions, such as expanding the indications or patient populations of some previously approved therapies.

Additionally, we allowed new dosage forms or drug formulations and made some prescription drugs available without a prescription.

The demographic shift towards an aging population significantly influences the Global Gastrointestinal Drugs Market Industry. Older adults are more susceptible to gastrointestinal disorders due to age-related physiological changes. According to demographic studies, the global population aged 65 and older is projected to double by 2050, leading to an increased prevalence of conditions such as gastroesophageal reflux disease and constipation. This demographic trend underscores the necessity for effective gastrointestinal treatments, thereby driving market growth. As the market is expected to grow at a CAGR of 5.06% from 2025 to 2035, the aging population will likely remain a critical driver of demand for gastrointestinal drugs.

The Global Gastrointestinal Drugs Market Industry is poised for substantial growth, with projections indicating a market value of 56.2 USD Billion in 2024 and an anticipated increase to 96.7 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 5.06% from 2025 to 2035. Such figures underscore the expanding demand for gastrointestinal medications driven by various factors, including the rising prevalence of gastrointestinal disorders, advancements in drug development, and increased healthcare expenditure. The market's evolution reflects a dynamic landscape, where ongoing research and innovation play pivotal roles in shaping future trends.

The upward trend in global healthcare expenditure is a significant driver for the Global Gastrointestinal Drugs Market Industry. Governments and private sectors are investing more in healthcare, leading to improved access to medications and treatments. According to health expenditure reports, many countries are allocating larger portions of their GDP to healthcare, which enhances the availability of gastrointestinal drugs. This financial commitment supports research and development, fostering innovation in drug therapies. As a result, the market is poised for growth, with projections indicating a rise to 96.7 USD Billion by 2035, reflecting the increasing prioritization of gastrointestinal health in healthcare budgets.

Innovations in drug development are pivotal for the Global Gastrointestinal Drugs Market Industry. The emergence of biologics and targeted therapies has transformed treatment paradigms for various gastrointestinal conditions. These advancements not only enhance efficacy but also improve patient compliance. For example, the introduction of monoclonal antibodies has shown promising results in treating inflammatory bowel diseases. As the market evolves, the integration of technology in drug formulation and delivery systems is expected to further propel growth. This trend aligns with the market's anticipated expansion to 96.7 USD Billion by 2035, indicating a robust pipeline of new therapeutic options.

Growing awareness regarding gastrointestinal health and advancements in diagnostic techniques are crucial for the Global Gastrointestinal Drugs Market Industry. Enhanced public knowledge about gastrointestinal disorders leads to earlier diagnosis and treatment, which is essential for effective management. The proliferation of health campaigns and educational initiatives has contributed to this awareness. Furthermore, improved diagnostic tools, such as endoscopy and imaging technologies, facilitate timely intervention. This trend is expected to boost the market as more individuals seek treatment, contributing to the projected market value of 56.2 USD Billion in 2024. Increased diagnosis correlates with higher demand for gastrointestinal medications.

The increasing incidence of gastrointestinal disorders globally drives the Global Gastrointestinal Drugs Market Industry. Conditions such as irritable bowel syndrome, Crohn's disease, and ulcerative colitis are becoming more prevalent, affecting millions. For instance, the World Health Organization reports that gastrointestinal diseases account for a significant portion of healthcare expenditures. This rising burden necessitates effective treatment options, contributing to the market's growth. As the market is projected to reach 56.2 USD Billion in 2024, the demand for innovative gastrointestinal drugs is likely to escalate, reflecting the urgent need for effective management of these conditions.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American gastrointestinal drugs market will dominate this market, owing to the presence of numerous market players and their varied strategic efforts.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  Gastrointestinal Drugs Market Share By Region 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's gastrointestinal drugs market accounts for the second-largest market share due to the rising healthcare sector investment and growing knowledge of digestive illnesses and their treatments. Another force in this area is the rising demand for the best and most efficient care. Further, the German gastrointestinal drugs market held the largest market share, and the UK gastrointestinal drugs market was the second-largest growing market in the European region.

The Asia-Pacific gastrointestinal drugs Market is expected to grow at the fastest CAGR from 2025 to 2034. This is due to densely populated countries like China and India. An escalating patient population, a growing elderly population, and escalating government investment efforts for healthcare facilities drive the rise in the Asia-Pacific area. Moreover, China’s gastrointestinal drugs market held the largest market share, and the Indian gastrointestinal drugs market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the Gastrointestinal Drugs market, grow even more. Additionally, market participants are engaging in a variety of strategic initiatives to increase their  footprint, with important market developments such as the introduction of new products, business contracts, mergers and acquisitions, increased investments, and cooperation with other organisations. To expand and survive in a more competitive and rising market climate, the gastrointestinal drugs industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the  gastrointestinal drugs industry to benefit clients and increase the market sector. In recent years, the gastrointestinal drugs industry has offered some of the most significant advantages to medicine. Major players in the gastrointestinal drugs market, including Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., and Sanofi.

Sanofi manufactures pharmaceutical products. The business sells prescription medications, over-the-counter remedies, food supplements, cosmetics, and medical equipment for conditions like diabetes, cancer, gynecology, and cardiology. Sanofi caters to clients all across the world. In May 2020, With the introduction of the new food supplement Buscobiota, Sanofi, a well-known producer of goods like Buscopan for irritable bowel syndrome and Dulcolax for constipation relief, entered the market for digestive health. Buscobiota, which contains two different forms of Bifidobacterium and three different types of Lactobacillus, can be taken as a preventative treatment for chronic constipation.

AbbVie Inc. researches and develops pharmaceutical products. The company produces pharmaceutical medications for specialized treatment fields like immunology, chronic renal disease, hepatitis C, women's health, oncology, and neuroscience. Multiple sclerosis, Parkinson's, and Alzheimer's disease are just a few of the illnesses that AbbVie treats. In March 2022, for treating moderately to highly active ulcerative colitis, the U.S. FDA gave AbbVie Inc. permission to use RINVOQ (upadacitinib), a new medication.